Royalty Total Current Assets from 2010 to 2025

RPRX Stock  USD 33.38  0.31  0.92%   
Royalty Pharma Total Current Assets yearly trend continues to be fairly stable with very little volatility. Total Current Assets will likely drop to about 1.6 B in 2025. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2016-12-31
Previous Quarter
1.8 B
Current Value
1.8 B
Quarterly Volatility
1.1 B
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 237.3 M, Total Revenue of 2.4 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.79, Dividend Yield of 0.0362 or PTB Ratio of 1.05. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of Royalty Pharma Plc over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Royalty Pharma's Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Slightly volatile
   Total Current Assets   
       Timeline  

Royalty Total Current Assets Regression Statistics

Arithmetic Mean1,196,247,353
Geometric Mean327,870,119
Coefficient Of Variation98.90
Mean Deviation1,059,141,353
Median1,274,193,000
Standard Deviation1,183,112,505
Sample Variance1399755.2T
Range2.9B
R-Value0.70
Mean Square Error766606.6T
R-Squared0.49
Significance0
Slope173,746,225
Total Sum of Squares20996328T

Royalty Total Current Assets History

20251.6 B
20241.8 B
20231.3 B
20222.6 B
20212.9 B
20202.7 B
2019832.1 M

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Total Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Assets1.8 B1.6 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.